NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it has reached an agreement with investors on the first half of a targeted $1.2 million private placement.

The firm said that 17 investors have agreed to purchase Pressure Bio shares for approximately $600,000 in the initial tranche. The investors include Pressure Bio's board of directors, officers of the firm, all members of the prior board of directors, and several existing investors in the company.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.